EQ Straddle Strategy

EQ (Equillium, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

EQ (Equillium, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $137.8M, a beta of 1.81 versus the broader market, a 52-week range of 0.76-3.54, average daily share volume of 685K, a public-listing history dating back to 2018, approximately 14 full-time employees. These structural characteristics shape how EQ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.81 indicates EQ has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a straddle on EQ?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

EQ snapshot

As of August 14, 2026, spot at $2.31, ATM IV 165.00%, IV rank 31.91%, expected move 47.30%. The straddle on EQ below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this straddle structure on EQ specifically: EQ IV at 165.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 47.30% (roughly $1.09 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EQ expiries trade a higher absolute premium for lower per-day decay. Position sizing on EQ should anchor to the underlying notional of $2.31 per share and to the trader's directional view on EQ stock.

EQ straddle setup

The EQ straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EQ at $2.31 on that close, the first option leg uses a $2.31 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EQ chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EQ shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$2.31N/A
Buy 1Put$2.31N/A

EQ straddle risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

EQ straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on EQ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on EQ

Straddles on EQ are pure-volatility plays that profit from large moves in either direction; traders typically buy EQ straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

EQ thesis for this straddle

The market-implied 1-standard-deviation range for EQ extends from approximately $1.22 on the downside to $3.40 on the upside. A EQ long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current EQ IV rank near 31.91% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on EQ should anchor more to the directional view and the expected-move geometry. As a Healthcare name, EQ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EQ-specific events.

EQ straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EQ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EQ alongside the broader basket even when EQ-specific fundamentals are unchanged. Always rebuild the position from current EQ chain quotes before placing a trade.

Frequently asked questions

What is a straddle on EQ?
A straddle on EQ is the straddle strategy applied to EQ (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With EQ stock at $2.31 on the most recent close, the strikes shown on this page are snapped to the nearest listed EQ chain strike and the premiums come straight from that session's bid/ask midpoint.
How are EQ straddle max profit and max loss calculated?
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the EQ straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 165.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a EQ straddle?
The breakeven for the EQ straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The EQ market-implied 1-standard-deviation expected move in the same options snapshot is approximately 47.30%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on EQ?
Straddles on EQ are pure-volatility plays that profit from large moves in either direction; traders typically buy EQ straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current EQ implied volatility affect this straddle?
EQ ATM IV is at 165.00% with IV rank near 31.91%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related EQ analysis